8-K: Astria Therapeutics Announces Positive Initial Data from HAE Clinical Trial, Plans Phase 3

Astria Therapeutics reports strong initial efficacy data from its Phase 1b/2 trial of STAR-0215 for hereditary angioedema (HAE), showing significant reductions in attack rates and rescue medication use, and plans to move into Phase 3 trials.

Summary

• Astria Therapeutics announced positive initial results from its Phase 1b/2 ALPHA-STAR clinical trial for STAR-0215, a treatment for hereditary angioedema (HAE).
• The trial included three cohorts with different dosing regimens, and all cohorts showed significant reductions in HAE attack rates.
• Cohort 1, with a 450mg dose, saw a 92% reduction in monthly attacks, a 96% reduction in moderate and severe attacks, and a 91% reduction in rescue medication use over 6 months.
• Cohort 2, with a 600mg dose followed by a 300mg dose, showed a 96% reduction in monthly attacks, a 98% reduction in moderate and severe attacks, and a 94% reduction in rescue medication use over 6 months.
• Cohort 3, with two 600mg doses, had a 90% reduction in monthly attacks, a 100% reduction in moderate and severe attacks, and a 95% reduction in rescue medication use over 3 months.
• The drug was generally well-tolerated with only two mild treatment-related adverse events.
• The company plans to move STAR-0215 into a Phase 3 trial with a Q3M dosing regimen, followed by a second trial for Q6M dosing.
• The Phase 3 trial is expected to start in the first quarter of 2025, with top-line results expected by the end of 2026.
• Astria has $246.5 million in cash as of December 31, 2023, plus $137.1 million from financing in Q1 2024, which is expected to fund operations into mid-2027.

Sentiment

Score: 8

Explanation: The document presents very positive initial clinical trial results, a clear path to Phase 3, and sufficient funding, indicating a strong positive sentiment.

Positives

• The initial data from the ALPHA-STAR trial demonstrates strong efficacy of STAR-0215 in reducing HAE attacks.
• The drug was well-tolerated with only mild adverse events.
• The rapid onset of action, particularly in Cohort 2, is a positive sign.
• The company has sufficient funding to complete the planned Phase 3 trial and advance other programs.
• The plan to pursue both Q3M and Q6M dosing regimens provides flexibility and potential for broader market reach.

Negatives

• There were two mild treatment-related adverse events, one case of dizziness and one transient injection site reaction.
• The Phase 3 trial is not expected to start until Q1 2025, with top-line results not expected until the end of 2026, which is a long timeline.

Risks

• The company faces risks inherent in pharmaceutical research and development, including the possibility of adverse results in clinical trials.
• There is a risk that the results of early-stage trials may not be replicated in later-stage trials.
• The company may face challenges in enrolling sufficient patients in clinical trials.
• Regulatory decisions and feedback from the FDA and other authorities could impact the development timeline.
• The company's ability to manufacture sufficient quantities of the drug and develop patient-friendly dosages is a risk.
• Competition in the HAE market could impact the success of STAR-0215.
• The company's cash usage and ability to obtain necessary financing are also risks.

Future Outlook

The company plans to initiate a Phase 3 trial for STAR-0215 in Q1 2025, with top-line results expected by the end of 2026, and expects its current cash position to fund operations into mid-2027.

Management Comments

• The observed efficacy, PK, PD, and safety and tolerability profile of STAR-0215 support advancement of STAR-0215 into Phase 3 development.
• The company plans to focus the Phase 3 program on Q3M dosing initially, immediately followed by a second trial to support label expansion to Q6M.

Industry Context

This announcement is significant in the HAE treatment landscape, as it presents a potential new therapy with strong efficacy data. The company is competing with existing treatments and other companies developing HAE therapies, and the success of STAR-0215 will depend on its performance in Phase 3 trials and its ability to compete in the market.

Comparison to Industry Standards

• The reported efficacy of STAR-0215, with up to 98% reduction in moderate and severe attacks, appears competitive with existing HAE treatments such as Takhzyro (lanadelumab) and Haegarda (C1 esterase inhibitor subcutaneous).
• Takhzyro, for example, has shown a reduction in HAE attack rates of around 87% in clinical trials, while Haegarda has shown a reduction of around 90%.
• The rapid onset of action observed in Cohort 2, with 100% of patients attack-free in the first month, is a notable advantage compared to some existing therapies.
• The safety profile of STAR-0215, with only mild adverse events, is also a positive factor compared to some other HAE treatments that may have more significant side effects.
• However, direct comparisons are difficult without head-to-head trial data, and the long-term efficacy and safety of STAR-0215 will need to be confirmed in Phase 3 trials.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and the plan to move into Phase 3.
• Patients with HAE may benefit from a new treatment option with a potentially improved efficacy and safety profile.
• Employees of Astria Therapeutics may be positively impacted by the company's progress and future prospects.
• The company's suppliers and partners may also benefit from the continued development of STAR-0215.

Next Steps

• The company plans to initiate a pivotal Q3M Phase 3 trial in the first quarter of 2025.
• The company will also conduct a second trial to support label expansion to Q6M dosing.
• Initial safety and efficacy data from Q3M and Q6M dosing in the ALPHA-SOLAR trial are expected in mid-2025.

Key Dates

Keywords

Hereditary Angioedema, HAE, STAR-0215, Clinical Trial, Phase 3, Pharmaceutical, Biotechnology, Drug Development, Efficacy, Safety